Ironwood Pharmaceuticals (Nasdaq: IRWD) is a GI-focused healthcare company dedicated to creating medicines that make a difference for patients living with GI diseases. We discovered, developed and are commercializing linaclotide, the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). We are also advancing two late-stage, first-in-category GI product candidates: IW-3718 is a gastric retentive formulation of a bile acid sequestrant being developed for the potential treatment of persistent gastroesophageal reflux disease, and MD-7246 is a delayed-release formulation of linaclotide that is being evaluated as an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from abdominal pain associated certain GI diseases. Source
No articles found.
CHF Solutions is focused on improving the quality of life for patients suffering f...
CHF Solutions is focused on improving the quali...
CytoDyn is a publicly traded late stage biotechnology company developing innovativ...
CytoDyn is a publicly traded late stage biotech...
Novan, Inc. is a clinical development-stage biotechnology company focused on lever...
Novan, Inc. is a clinical development-stage bio...
At MannKind Corporation (NASDAQ: MNKD), we focus on the discovery, development and...
At MannKind Corporation (NASDAQ: MNKD), we focu...
Rigel Pharmaceuticals, Inc. is a biotechnology company dedicated to discovering, d...
Rigel Pharmaceuticals, Inc. is a biotechnology ...
Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to ...
Rexahn Pharmaceuticals is a clinical stage biop...
Novan, Inc. is a clinical development-stage biotechnology company focused on lever...
Novan, Inc. is a clinical development-stage bio...
Join the National Investor Network and get the latest information with your interests in mind.